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STROKE-ASSOCIATED PNEUMONIA AND
ACUTE STROKE: FREQUENCY,
PROGNOSTIC VALUE AND IMPACT OF
COMORBIDITIES
Abstract. The aim of research was to evaluate the frequency of
nosocomial pneumonia and other hospital-acquired complications
after acute ischemic stroke, to assess the impact of somatic
comorbidity on pneumonia occurrence, and to determine the relation
of pneumonia to 28-day stroke case fatality. Methods. We performed a
prospective study among 207 patients hospitalized for acute ischemic
stroke. Stroke severity was evaluated with National Institutes of
Health Stroke Scale. Somatic comorbidity was analyzed and graded
with Modified Charlson Comorbidity Index. Post-stroke complications
were diagnosed using standardized criteria. Results. Mean score of
the admission stroke severity in all patients was 12.3±0.4. Of all
strokes, 87.4% developed against a background3 2 of preexisting
somatic pathology. Low comorbidity was recorded in 101 patients
(48.8%), moderate – in 58 (28.0%), high – in 48 (23.2%); mean
Charlson index score was 1.8±0.07. During admission, one or more
medical complications occurred in 61 patients (29.5%). The frequency
of pneumonia was 19.3% (40 cases): 27.8% in patients with fatal
stroke vs. 8.7% in stroke survivors (ð<0.01). The highest was the
frequency of pneumonia in patients with high comorbidity (37.5%)
compared to those with low (11.9%) or moderate index scores
(17.2%). The further analysis showed positive correlation between the
increase of Charlson comorbidity index and pneumonia occurrence
(rpb=0,389). Nosocomial pneumonia was related to 28 days case
fatality in ischemic stroke (φ=0,241) and this complication
significantly increased the probability of death in acute period –
OR=3.94 (95% CI 1.59-9.76). Conclusions. Nosocomial pneumonia
is a life-threatening complication that affects almost every 5th patient
with acute ischemic stroke. The occurrence of stroke-associated
pneumonia positively correlates with the higher level of preexisting
somatic comorbidity. Development of pneumonia after acute ischemic
stroke is an adverse prognostic factor, which increases the probability
of 28-days case fatality by 3.9-fold.
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Introduction
Patients with acute stroke are at high risk of
experiencing a wide range of complications, some of
which can be life threatening. These new or
exacerbated medical problems may hamper
rehabilitation efforts, prevent optimal recovery,
prolong the hospital stay, and ultimately worsen
stroke outcome [2]. Neurological complications arise
due to direct damaging of the brain and its arachnoid
membranes. Together with the initial stroke severity
they become the main contributors to the early case
fatality rate after acute stroke, while the likelihood of
death in 30-days period is commonly related to the
patient’s age and somatic complications of stroke, as
well as to preexisting comorbidity [12].
Several previous studies have suggested that the
estimated frequency of extracerebral poststroke
complications ranges from 27.6 to 59%, which may
be due to different inclusion and diagnostic criteria [2,
7]. The commonest among them are nosocomial chest
and urinary tract infections that affect on the average 1/
3 of stroke patients [1]. The other complications include
thromboembolism such as deep vein thrombosis and
pulmonary embolism, trophic disorders (pressure
sores), gastrointestinal hemorrhage, episodes of cardiac
failure, kidney failure etc. [2, 9].
The probability of complications is directly pro-
portional to the severity of stroke and is the major
cause of fatal cases in the 2nd and 3rd weeks of
disease [15]. Somatic complications have a
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significant impact on the long-term prognosis of
stroke as they increase the risk of 4-years case
fatality by 48.3%. They present potential barriers to
optimal recovery and rehabilitation, intensify
neuronal damage and neurological deficit; increase
the risk of stroke recurrence [2].
Nosocomial pneumonia is a common somatic
complication after acute stroke [7, 9]. It accounts for
approximately 10% of stroke-related deaths during
the hospital stay and increases mortality rate by
three-fold [6]. The frequency of pneumonia during
inpatient rehabilitation varies between the studies,
but estimates have been reported to range between
8.2 and 21.4% [1, 6, 10, 15] with the maximum of
50% in severe stroke [11]. Peak of the disease is
observed on the first week after stroke onset [1, 9] with
the fatality rate up to 20-50% [7, 13]. Contributory factors
for pneumonia in acute stroke include dysphagia, the use
of mechanical ventilation [7], impaired pharyngeal and
cough reflex, aspiration, dehydration, immobility and
expiratory muscle weakness [1].
It has been shown that pneumonia is associated
with an increase of early case fatality rate in ischemic
stroke by 3-fold, and late case fatality by 2.5-fold. It
also deepens the severity of functional deficit and
slows the recovery of neurological functions [7]. In
another study a 5.1-fold increase of 90-days stroke
fatality and strong correlation of nosocomial pneu-
monia with the extent of patient disability and de-
pendence was reported [1]. Early development of
pneumonia after ischemic stroke is associated with the
older age of patient, higher baseline stroke severity
score, impairment of consciousness, central paresis of
facial nerve [3], speech disorders (dysarthria or no
speech due to aphasia), cognitive decline and general
severity of poststroke disability [13].
Somatic comorbidities are also found to have an
impact on complications after stroke. Thus chronic
obstructive pulmonary disease (COPD) leads to a
5.3-fold increase of frequency of nosocomial
pneumonia [13]. The risk of this complication after
ischemic stroke is elevated by the preexisting atrial
fibrillation and congestive heart failure, and at the
same time it is substantially decreased in patients
with dementia [10]. The other investigators point out
diabetes mellitus as a prognostic factor for
pneumonia [1].
Despite the seriousness of pneumonia as a stroke
complication this disease is potentially preventable
and treatable if recognized in time, that sustantially
improve the consequences of the disease. The first
step towards effective prevention is obtaining accurate
data about the incidence of different medical
conditions that follow acute stroke. Although many
studies have reported frequencies of poststroke
complications, particularly pneumonia, the results vary
significantly due to methodological bias. Getting
reliable information is impossible without a clearly
defined cohort of patients, prospective design of the
study, standardized definitions of complications and
follow-up of all patients for a prolonged period of time.
The second step is identifying clinical factors that
are independently related to the occurrence of a medical
complication which is essential for appropriate
preventive measures and management. Third,
knowledge of onset and course of typical complications
following acute stroke is mandatory to determine the
duration of close monitoring and acute care.
The aim of research
To evaluate the frequency of nosocomial pneu-
monia and other hospital-acquired complications
after acute ischemic stroke, to assess the impact of
somatic comorbidity on pneumonia occurrence, and
to determine the relation of pneumonia to 28-day
stroke case fatality.
Methods
We performed a prospective study among
hospitalized patients admitted to the neurology
department and intensive care unit of Chernivtsi
municipal clinical hospital No3. We examined 207
patients within 5 days of stroke onset with the
consecutive follow-up until the 28-s day of the
disease. Mean (SD) age of patients was 69.4±11.5
years. 46.4% were men (96 patients) and 53.6%
women (111 patients).
Patients were examined within 24 hours after
hospitalization. Stroke was diagnosed according to
WHO criteria [14]. Ischemic stroke subtype was
defined on the basis of clinical analysis and neuro-
imaging data (in 102 patients). In fatal cases the
diagnosis was verified by autopsy results.
Stroke severity was evaluated with National
Institutes of Health Stroke Scale, NIHSS (T. Brott et
al., 1989), which is a simple, reliable and validated
scale whereby higher scores indicate more severe
stroke. Somatic comorbidity was analyzed after
consultation of the specialists, studying patients’
medical documentation and history. For qualitative
assessment of comorbidity we used Charlson
Comorbidity Index (M.E. Charlson et al., 1987)
modified for the stroke outcome studies [5]. The
Charlson index provides an approach to classifying
comorbid diseases. It consists of a weighted count of
17 serious medical conditions that was originally
developed to predict 1-year mortality among
hospitalized patients but since has been widely used
in health services research. According to the modified
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Charlson index all patients were divided into three
groups for analysis: 0 or 1 – low comorbidity, 2 –
moderate and ≥3 – high comorbidity.
During prospective follow-up we recorded the
occurrence of extracerebral complications, parti-
cularly nosocomial pneumonia. Stroke-associated
pneumonia was diagnosed using standardized Mann
criteria [3]. Subjects were required to have 3 or more
of the following characteristics: fever (≥38°C),
productive cough with purulent sputum, abnormal
respiratory examination (tachypnea ≥22/min, tachy-
cardia, inspiratory crackle, bronchial breathing),
abnormal chest radiographic findings, arterial
hypoxemia (PO2 ≤70 mm Hg or SpO2 ≤94%), and
isolation of a relevant pathogen (positive Gram’s
stain and culture). Among the other complications
we recorded urinary tract infection, pressure sores,
thromboembolism, and acute heart failure.
During 28-day period after stroke onset 115
deaths were registered (56 men and 59 women). For
the further analysis all stroke cases were grouped
into two categories: fatal and non-fatal strokes (115
and 92 cases respectively).
All patients received basic treatment and after
stroke subtype verification – differential therapy
according to the existing standards. This precluded the
influence of medication on the sample assessment.
Statistical analysis was performed with an open
access software package OpenOffice.org Calc
(version 2.0.4), Sun Microsystems Inc. and
Microsoft® Excel. x2 tests were used to compare
categorical variables; Student’s t tests and median 2-
sample tests were used for continuous variables. The
degree of relationship between two dichotomous
(binary) variables was computed with mean square
contingency coefficient (ϕ correlation coefficient).
The correlation between two variables when one is
dichotomous and the other is continuous was
calculated with point biserial correlation coefficient
(rpb). All tests were 2 tailed, and probability values
<0.05 were considered significant. The probability of
the outcome or the strength of association between
two binary data values was analyzed with odds ratio
(OR) and its confidence intervals (CI) with p=0.05.
Results
After a complete neurological examination the
admission stroke severity in 29 patients (14.0%) was
given NIHSS score of 1-4, which meant minor
stroke. Neurological deficit in more than a half of
patients (51.7%) was moderate – NIHSS 5-14.
Moderate/severe stroke (NIHSS 15-20) was found in
46 (22.2%) and severe stroke (NIHSS 21-40) was
diagnosed in 25 (12.1%) patients. Mean score of all
ischemic stroke patients was 12.3±0.4.
In 87.4% of patients, ischemic stroke developed
against a background of preexisting somatic patho-
logy. According to the Charlson index components
the frequencies of the comorbidities were the
following: history of myocardial infarction or
unstable angina – 33 patients (15.9%), congestive
heart failure – 144 (69.6%), diabetes (uncom-
plicated) – 34 (16.4%), diabetes (complicated) – 15
(7.2%), chronic pulmonary disease – 39 (18.8%),
peripheral vascular disease – 12 (5.8%), peptic ulcer
disease – 11 (5.3%), rheumatologic disease – 10
(4.8%), dementia – 7 (3.4%), chronic renal failure – 6
(2.9%), mild liver disease – 7 (3.4%), moderate to
severe liver disease – 4 (1.9%), any malignancy (non-
metastatic, excluding full remission ≥5 years) – 5
(2.4%), leucosis – 1 patient (0.5%).
Baseline modified Charlson index scores ranged
from 0 to 9 with a mean of 1.8±0.07. Low
comorbidity was registered in 101 (48.8%) patients,
moderate – in 58 (28.0%) and high – in 48 (23.2%).
A total of 61 patients (29.5%) experienced at least
1 prespecified complication during their stay in
hospital. Hospital-acquired pneumonia appeared to
be the most common somatic complication; it was
diagnosed clinically and/or confirmed by autopsy in
40 cases. The overall frequency of pneumonia was
19.3%. 62.5% of pneumonia cases were registered
within 7 days of stroke onset. The other compli-
cations included: urinary tract infection – 8.7%,
pressure sores – 5.8%, thromboembolism – 3.9%,
and acute heart failure – 2.9%.
Of all stroke patients diagnosed with pneumonia
32 died within 28 days of stroke onset. The overall
frequency of nosocomial pneumonia in patients with
fatal stroke compared to stroke survivors was 27.8%
vs. 8.7% (ð<0.01).
We have analyzed the level of preexisting somatic
comorbidity in the cohort of patients with pneu-
monia. The results are presented in Table.
The data from the Table show that the frequency
of nosocomial pneumonia was significantly higher in
patients with Charlson index ≥3, compared to those
with low or moderate level of comorbidity.
After the assessment of connection between the
level of the preexisting somatic comorbidity and
stroke-associated pneumonia we have found that the
increase of Charlson comorbidity index is signi-
ficantly related to pneumonia occurrence with the
moderate strength of relation – rpb=0,389.
Association of pneumonia with comorbidity is an
issue of special interest because it expands the
capability of preventive measures. Pneumonia after
stroke may be caused either by aspiration or
hypostasis [11]. Aspiration after stroke is a
consequence of bulbar disorder as a sign of focal
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lesion or central inhibition of laryngeal cough reflex,
as well as the reflex that provides the spasm of glottis
in patients with severe impairment of consciousness
[7]. Besides, extensive lesion of the brain with
pronounced cerebral and focal signs is accompanied
by the impairment of non-specific immune protection
mechanisms including local and humoral immunity,
which facilitates chest infection [11]. Taking into
consideration the correlations of Charlson index with
the level of consciousness and neurological severity
of stroke, which were reported in our previous
studies [4], it becomes possible that patients with
high comorbidity are inclined to the occurrence of
aspiration pneumonia. On the other hand, severe
somatic comorbidity essentially restricts adequate
rehabilitation [8] that increases the frequency of
hypostatic pneumonia. In any case, prevention, early
detection and proper management of pneumonia
during the acute stage of ischemic stroke could
essentially improve short-term prognosis after stroke.
Because our goal was to determine the impact of
pneumonia on stroke outcome, we have studied the
association of this complication with fatal stroke.
The analysis with the mean square contingency
coefficient has confirmed that the occurrence of
pneumonia is directly positively related to 28 days
case fatality in ischemic stroke – ϕ=0,241. This
relation is weak by strength however statistically
significant. Computation of OR coefficient has
shown that pneumonia increases the probability of
death by almost 4-fold – OR=3.94 (95% CI 1.59-
9.76). This result adds to the evidence that nosocomial
pneumonia is a threatening medical condition, which
substantially influences stroke mortality.
Conclusions
1. Nosocomial pneumonia is a life-threatening
complication that affects almost every 5th patient
with acute ischemic stroke.
2. The occurrence of stroke-associated pneu-
monia positively correlates with the higher level of
preexisting somatic comorbidity.
3. Pneumonia after acute ischemic stroke is an
adverse prognostic factor, which increases the
probability of 28-days case fatality by 3.9-fold.
Perspectives of the future research
The further research should be aimed at studying
the impact of separate comorbidities on the risk of
post-stroke complications, particularly chest
infection. Definition of new baseline factors that
predict occurrence of any complication will assist in
the early screening and monitoring of patients as well
as in decreasing stroke mortality.
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ÍÎÇÎÊÎÌ²ÀËÜÍÀ ÏÍÅÂÌÎÍ²ß ÒÀ ÃÎÑÒÐÈÉ
²ÍÑÓËÜÒ: ×ÀÑÒÎÒÀ ÂÈÍÈÊÍÅÍÍß,
ÏÐÎÃÍÎÑÒÈ×ÍÅ ÇÍÀ×ÅÍÍß ÒÀ ÂÏËÈÂ
ÑÓÏÓÒÍÜÎ¯ ÑÎÌÀÒÈ×ÍÎ¯ ÏÀÒÎËÎÃ²¯
O. O. Ô³ë³ïåöü, Â. Ì. Ïàøêîâñüêèé
Ðåçþìå. Âèâ÷åíî ÷àñòîòó ðîçâèòêó íîçîêîì³àëüíî¿ ïíåâ-
ìîí³¿ òà ³íøèõ âíóòð³øíüîãîñï³òàëüíèõ åêñòðàöåðåáðàëüíèõ
óñêëàäíåíü ó 207 ïàö³ºíò³â ³ç ãîñòðèì ³øåì³÷íèì ³íñóëüòîì.
Âèçíà÷åíî ïîøèðåí³ñòü ôîíîâî¿ ñîìàòè÷íî¿ ïàòîëîã³¿ òà
ïðîâåäåíî ¿¿ ÿê³ñíó îö³íêó ç âèêîðèñòàííÿì ìîäèô³êîâàíî-
ãî ³íäåêñó êîìîðá³äíîñò³ ×àðëñîíà. Âñòàíîâëåíî, ùî ÷àñòîòà
ðîçâèòêó ³íñóëüò-àñîö³éîâàíî¿ ïíåâìîí³¿ ñóòòºâî âèùà â õâî-
ðèõ ³ç âèñîêèì ð³âíåì ñóïóòíüî¿ ñîìàòè÷íî¿ ïàòîëîã³¿, í³æ ó
ïàö³ºíò³â ³ç íèçüêîþ àáî ïîì³ðíîþ êîìîðá³äí³ñòþ. Çðîñòàí-
íÿ ³íäåêñó äîñòîâ³ðíî ïîçèòèâíî êîðåëþº ç ðîçâèòêîì öüî-
ãî óñêëàäíåííÿ ç ïîì³ðíîþ ñèëîþ çâ’ÿçêó – rpb=0,389. Âè-
íèêíåííÿ ïíåâìîí³¿ ìàº äîñòîâ³ðíèé êîðåëÿö³éíèé çâ’ÿçîê
³ç 28-äåííîþ ëåòàëüí³ñòþ ïðè ³øåì³÷íîìó ³íñóëüò³ –
ϕ=0,241. Âèçíà÷åííÿ àñîö³àö³¿ ïíåâìîí³¿ ç ëåòàëüí³ñòþ çà
äîïîìîãîþ ïîêàçíèêà â³äíîøåííÿ øàíñ³â ïîêàçàëî, ùî ðîç-
âèòîê óñêëàäíåííÿ ï³äâèùóº ðèçèê ôàòàëüíîãî íàñë³äêó
³øåì³÷íîãî ³íñóëüòó â 3,94 ðàçó (95% Ä² 1,59-9,76). Òàêèé
ðåçóëüòàò ï³äòâåðäæóº, ùî íîçîêîì³àëüíà ïíåâìîí³ÿ º çàã-
ðîçëèâèì óñêëàäíåííÿì, ÿêå ñóòòºâî âïëèâàº íà ñìåðòí³ñòü
â³ä ³íñóëüòó. Ïðîô³ëàêòèêà, ðàííÿ ä³àãíîñòèêà òà åôåêòèâíå
ë³êóâàííÿ ïíåâìîí³¿ ó ãîñòð³é ñòàä³¿ ³øåì³÷íîãî ³íñóëüòó
ìîæå çíà÷íî ïîêðàùèòè ðàíí³é ïðîãíîç çàõâîðþâàííÿ.
Êëþ÷îâ³ ñëîâà: ³øåì³÷íèé ³íñóëüò, ïíåâìîí³ÿ, êî-
ìîðá³äí³ñòü, ïðîãíîç.
Áóêîâèíñüêèé äåðæàâíèé ìåäè÷íèé óí³âåðñèòåò
ÍÎÇÎÊÎÌÈÀËÜÍÀß ÏÍÅÂÌÎÍÈß È ÎÑÒÐÛÉ
ÈÍÑÓËÜÒ: ×ÀÑÒÎÒÀ ÂÎÇÍÈÊÍÎÂÅÍÈß,
ÏÐÎÃÍÎÑÒÈ×ÅÑÊÎÅ ÇÍÀ×ÅÍÈÅ È ÂËÈßÍÈÅ
ÑÎÏÓÒÑÒÂÓÞÙÅÉ ÑÎÌÀÒÈ×ÅÑÊÎÉ
ÏÀÒÎËÎÃÈÈ
Å.À. Ôèëèïåö, Â.Ì. Ïàøêîâñêèé
Ðåçþìå. Èçó÷åíà ÷àñòîòà ðàçâèòèÿ íîçîêîìèàëüíîé
ïíåâìîíèè è äðóãèõ âíóòðèãîñïèòàëüíûõ ýêñòðàöåðåáðàëü-
íûõ îñëîæíåíèé ó 207 ïàöèåíòîâ ñ îñòðûì èøåìè÷åñêèì
èíñóëüòîì. Èññëåäîâàíà ðàñïðîñòðàíåííîñòü ôîíîâîé ñîìà-
òè÷åñêîé ïàòîëîãèè è ïðîâåäåíà åå êà÷åñòâåííàÿ îöåíêà ñ
èñïîëüçîâàíèåì ìîäèôèöèðîâàííîãî èíäåêñà êîìîðáèäíî-
ñòè ×àðëñîíà. Óñòàíîâëåíî, ÷òî ÷àñòîòà ðàçâèòèÿ èíñóëüò-
àññîöèèðîâàííîé ïíåâìîíèè ñóùåñòâåííî âûøå ó áîëüíûõ
ñ âûñîêèì óðîâíåì ñîïóòñòâóþùåé ñîìàòè÷åñêîé ïàòîëîãèè,
÷åì ó ïàöèåíòîâ ñ íèçêîé ëèáî óìåðåííîé êîìîðáèäíîñòüþ.
Óâåëè÷åíèå èíäåêñà äîñòîâåðíî ïîëîæèòåëüíî êîððåëèðóåò
ñ ðàçâèòèåì ýòîãî îñëîæíåíèÿ ñ óìåðåííîé ñèëîé ñâÿçè –
rpb=0,389. Ïðèñîåäèíåíèå ïíåâìîíèè ïîêàçûâàåò äîñòîâåð-
íóþ êîððåëÿöèîííóþ ñâÿçü ñ 28-äíåâíîé ëåòàëüíîñòüþ ïðè
èøåìè÷åñêîì èíñóëüòå – ϕ=0,241. Îïðåäåëåíèå àññîöèàöèè
ïíåâìîíèè ñ ëåòàëüíîñòüþ ïðè ïîìîùè ïîêàçàòåëÿ îòíîøå-
íèÿ øàíñîâ ïîêàçàëî, ÷òî ðàçâèòèå îñëîæíåíèÿ ïîâûøàåò
ðèñê ôàòàëüíîãî èñõîäà èøåìè÷åñêîãî èíñóëüòà â 3,94 ðàçà
(95% ÄÈ 1,59-9,76). Òàêîé ðåçóëüòàò ïîäòâåðæäàåò, ÷òî íî-
çîêîìèàëüíàÿ ïíåâìîíèÿ ÿâëÿåòñÿ óãðîæàþùèì îñëîæíåíè-
åì, êîòîðîå ñóùåñòâåííî âëèÿåò íà ñìåðòíîñòü îò èíñóëüòà.
Ïðîôèëàêòèêà, ðàííÿÿ äèàãíîñòèêà è ýôôåêòèâíîå ëå÷åíèå
ïíåâìîíèè â îñòðîé ñòàäèè èøåìè÷åñêîãî èíñóëüòà ìîæåò
çíà÷èòåëüíî óëó÷øèòü ðàííèé ïðîãíîç çàáîëåâàíèÿ.
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